<SEC-DOCUMENT>0001104659-23-074396.txt : 20230626
<SEC-HEADER>0001104659-23-074396.hdr.sgml : 20230626
<ACCEPTANCE-DATETIME>20230623194746
ACCESSION NUMBER:		0001104659-23-074396
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230626
DATE AS OF CHANGE:		20230623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nutex Health, Inc.
		CENTRAL INDEX KEY:			0001479681
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				113363609
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-267686
		FILM NUMBER:		231039188

	BUSINESS ADDRESS:	
		STREET 1:		2455 EAST SUNRISE BLVD.
		STREET 2:		SUITE 1204
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33304
		BUSINESS PHONE:		(954) 449-4703

	MAIL ADDRESS:	
		STREET 1:		2455 EAST SUNRISE BLVD.
		STREET 2:		SUITE 1204
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Clinigence Holdings, Inc.
		DATE OF NAME CHANGE:	20191113

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	iGambit, Inc.
		DATE OF NAME CHANGE:	20091230
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>tm2310592d6_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0; color: red"><FONT STYLE="color: Black">Filed pursuant
to Rule 424(b)(3) <BR>
File No. 333-267686</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm2310592d6_424b3img001.jpg" ALT="https:||www.sec.gov|Archives|edgar|data|1479681|000160706222000608|image_001.jpg" STYLE="height: 61px; width: 473px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nutex Health&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>90,226,077 Shares of Common Stock Offered by
the Selling Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus relates to the resale of an aggregate of
90,226,077 shares of common stock, par value $0.001 per share (&ldquo;Common Stock&rdquo;), held by former holders of member
interests of Nutex Health Holdco LLC, now a wholly owned subsidiary of Nutex Health Inc. Please read &ldquo;Selling
Stockholders&rdquo; for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will not receive any proceeds from the sale of the shares of Common
Stock by the selling stockholders. For a detailed discussion of the selling stockholders, see &ldquo;Selling Stockholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus describes the general terms of the shares of Common
Stock and the general manner in which the selling stockholders will offer them. An accompanying prospectus supplement, if any, will describe
the specific manner in which the selling stockholders will offer the shares of Common Stock, and also may add, update or change information
contained in this prospectus. The names of any underwriters, dealers, agents or other entities and the specific terms of a plan of distribution
with respect to any offering of securities will be stated in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should read this prospectus and any applicable prospectus supplement
and the documents incorporated by reference herein or therein carefully before you invest in any of the shares of Common Stock. You should
also read the documents we have referred you to in the &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Information We Incorporate
by Reference&rdquo; sections of this prospectus for information about us, including our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Common Stock trades on the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;)
under the ticker symbol &ldquo;NUTX&rdquo;. On June 22, 2023, the closing sale price of our Common Stock as reported by NASDAQ was
$0.5126 per share. You are urged to obtain current market quotations for the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in shares of our Common Stock involves a high degree of
risk. You should carefully read the &ldquo;Risk Factors&rdquo; section beginning on page&nbsp;<A HREF="#sp1_002">2</A> and the risks discussed in the documents
we file with the United States Securities and Exchange Commission and that are incorporated by reference herein.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the United States Securities and Exchange Commission nor any state
securities commission has approved or disapproved of the securities to be issued under this prospectus or determined whether this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 25%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is June 23,
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 96%"><A HREF="#sp1_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="width: 4%; text-align: right"><A HREF="#sp1_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp1_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp1_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp1_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY NOTE&nbsp;REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp1_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp1_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OUR COMPANY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp1_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp1_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp1_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp1_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp1_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp1_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SELLING STOCKHOLDERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp1_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp1_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp1_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp1_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp1_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp1_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp1_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp1_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp1_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp1_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp1_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp1_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp1_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>We have not authorized anyone to provide you
with any information other than the information contained in this prospectus, any future prospectus supplement prepared by us or incorporated
by reference in this prospectus or any prospectus supplement. We do not take any responsibility for, and can provide no assurance as to
the reliability of, any other information that others may give you. We are not offering these securities in any state where the offer
is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>You should not assume that the information contained
in this prospectus, any prospectus supplement or the documents incorporated by reference in this prospectus or in any prospectus supplement
is accurate as of any date other than the respective dates of those documents.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sp1_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus is part of a registration statement
that we have filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) using a &ldquo;shelf&rdquo; registration process.
Under this shelf registration process, the selling stockholders may from time to time re-sell up to an aggregate 90,226,077 shares of
our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus provides you with a general description
of Nutex Health&nbsp;Inc. and the securities that are registered hereunder. Each time a selling stockholder sells shares of Common Stock
with this prospectus, such selling stockholder is required to provide you with this prospectus and any related prospectus supplement containing
specific information about the terms of that offering. Any prospectus supplement may also add to, update or change information contained
in this prospectus. To the extent information in this prospectus is inconsistent with the information contained in a prospectus supplement,
you should rely on the information in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information in this prospectus is accurate
as of its date. Additional information, including our financial statements and the notes thereto, is incorporated in this prospectus by
reference to our reports filed with the SEC and is accurate as of the date stated in such report. Before you invest in our securities,
you should carefully read this prospectus, including the &ldquo;Risk Factors,&rdquo; any prospectus supplement, the information incorporated
by reference in this prospectus and any prospectus supplement (including the documents described under the heading &ldquo;Where You Can
Find More Information&rdquo; in both this prospectus and any prospectus supplement) and any additional information you may need to make
your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As used in this prospectus, unless otherwise indicated
or the context otherwise requires, references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company,&rdquo; and
 &ldquo;Nutex Health&rdquo; refer to the consolidated operations of Nutex Health&nbsp;Inc., a Delaware corporation, and its consolidated
subsidiaries following the merger (the &ldquo;Merger&rdquo;), on April&nbsp;1, 2022, of Nutex Health Holdco LLC and Clinigence Holdings,&nbsp;Inc.
(&ldquo;Clinigence&rdquo;) as contemplated by the Agreement and Plan of Merger (the &ldquo;Merger Agreement&rdquo;) dated as of November&nbsp;23,
2021 between Clinigence, Nutex Acquisition LLC, a wholly-owned subsidiary of Clinigence, Nutex, Micro Hospital Holding LLC (solely for
the purposes of certain sections of the Merger Agreement), Nutex Health Holdco LLC and Thomas Vo, M.D., solely in his capacity as the
representative of the equity holders of Nutex Health Holdco&nbsp;LLC. Immediately after the Merger, Clinigence changed its name to &ldquo;Nutex
Health&nbsp;Inc.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">References to &ldquo;Clinigence&rdquo; refer to
the Company prior to the consummation of the Merger, references to &ldquo;Nutex&rdquo; refer to Nutex Health and its affiliates prior
to the consummation of the Merger of Clinigence Holdings,&nbsp;Inc. and Nutex Health Holdco LLC, and references to &ldquo;Nutex Holdco&rdquo;
refer to Nutex Health Holdco LLC following the consummation of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sp1_002"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Investing in our Common Stock involves a high degree
of risk. You should carefully consider the risks set forth in our filings with the SEC that are incorporated by reference herein and any
prospectus supplement, as well as other information we include or incorporate by reference into this prospectus and any applicable prospectus
supplement, before making an investment decision. Our business, financial condition or results of operations could be materially adversely
affected by the materialization of any of these risks. The trading price of our Common Stock could decline due to the materialization
of any of these risks, and you may lose all or part of your investment. This prospectus and the documents incorporated herein by reference
also contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated
in these forward-looking statements as a result of certain factors, including the risks described in the documents incorporated herein
by reference, including our most recent Annual Report on Form&nbsp;10-K, our Quarterly Reports on Form&nbsp;10-Q and our Current Reports
on Form&nbsp;8-K that are incorporated by reference herein and the other documents we file with the SEC that are deemed incorporated by
reference into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sp1_003"></A>CAUTIONARY NOTE&nbsp;REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus, any accompanying prospectus supplement
and the documents incorporated by reference herein and therein contain &ldquo;forward-looking statements&rdquo; within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). We intend such forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and include this statement
for purposes of complying with these safe harbor provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This document contains certain forward-looking
statements with respect to our financial condition, results of operations and business, plans, objectives and strategies. These statements
may be made directly in this prospectus or may be incorporated by reference to other documents or in any accompanying prospectus supplement.
These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking
statements often use words such as &ldquo;estimate,&rdquo; &ldquo;project,&rdquo; &ldquo;predict,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo;
 &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo; &ldquo;intend,&rdquo;
 &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;aim,&rdquo; &ldquo;goal,&rdquo; &ldquo;target,&rdquo; &ldquo;objective,&rdquo; &ldquo;commit,&rdquo;
 &ldquo;advance,&rdquo; &ldquo;likely&rdquo; or similar expressions that convey the prospective nature of events or outcomes. There are
several factors which could cause actual plans and results to differ materially from those expressed or implied in forward-looking statements.
Such factors include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our ability to successfully execute our growth strategy, including identifying and developing successful new geographies, physician
partners and patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>changes in applicable laws or regulations, including changes in the laws and regulations related to reimbursements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>uncertainties in the amounts, timing and process of reimbursements by third-party payors and individuals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>we may be adversely affected by other economic, business, and/or competitive factors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the difficulty in evaluating our future prospects, as well as risks and challenges, due to the new and rapidly evolving business and
market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>we may need to raise additional capital to fund our existing operations, develop and commercialize new services or expand our operations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>possible difficulty managing growth and expanding operations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the continuing impact of the COVID-19 pandemic on operations, which may materially and adversely affect our business and financial
results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our ability to retain qualified personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the effectiveness and efficiency of our marketing efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>spending changes in the healthcare industry;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>we, our affiliated professional entities, and other physician partners may become subject to medical liability claims;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>a failure in our information technology systems;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>security breaches, loss of data or other disruptions could compromise sensitive information related to our business or prevent us
from accessing critical information, expose us to liability and our reputation may be harmed and we could lose sales, clients and members;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any future litigation against us could be costly and time-consuming to defend;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>failure to adhere to all of the complex government laws and regulations that apply our business could result in fines or penalties,
being required to make changes to its operations or experiencing adverse publicity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our arrangements with affiliated professional entities and other physician partners may be found to constitute improper rendering
of medical services or fee splitting under applicable state laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>we may face inspections, reviews, audits and investigations under federal and state government programs and contracts and adverse
findings may have an adverse effect on our business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>recent healthcare legislation and other changes in the healthcare industry and in healthcare spending has and may in the future adversely
affect our revenues and may cause material adverse effects on our financial results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the transition from volume to value-based reimbursement models may have a material adverse effect on our operations; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>other risks and uncertainties described in this prospectus, including those under the section entitled &ldquo;Risk Factors.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These forward-looking statements reflect our current
views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception
of historical trends, current conditions, business strategies, operating environments, future developments and other factors we believe
appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events
and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in
this document could cause our plans, actual results, performance or achievements, industry results and developments to differ materially
from those expressed in or implied by such forward-looking statements. Although we believe that the expectations reflected in such forward-looking
statements are reasonable, we cannot assure you that such expectations will prove to have been correct and persons reading this document
are therefore cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this prospectus
or, in the case of a document incorporated by reference, as of the date of that document. We do not assume any obligation to update the
information contained in this document (whether as a result of new information, future events or otherwise), except as required by applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sp1_004"></A>OUR COMPANY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a physician-led, healthcare services and
operations company with 19 hospital facilities in eight states (&ldquo;hospital division&rdquo;), and a primary care-centric, risk-bearing
population health management division. Our hospital division implements and operates innovative health care models, including micro-hospitals,
specialty hospitals and hospital outpatient departments. The population health management division owns and operates provider networks
such as independent physician associations (&ldquo;IPAs&rdquo;) and offers a cloud-based proprietary technology platform to IPAs which
aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and
providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We employ approximately 1,200 full and part-time employees and
partner with over 900 physicians. Our corporate headquarters is based in Houston, Texas. We were incorporated on April&nbsp;13, 2000 in
the state of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sp1_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will not receive any of the proceeds from the
sale of Common Stock by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sp1_006"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information regarding
the beneficial ownership of shares of the Common Stock by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>each person known by the Company to be the beneficial owner of more than 5% of the shares of the Company&rsquo;s Common Stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>each of the Company&rsquo;s named executive officers and directors; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>all officers and directors of the Company as a group.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Beneficial ownership is determined according to
the rules&nbsp;of the Commission, which generally provide that a person has beneficial ownership of a security if he, she or it possesses
sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable
within 60&nbsp;days of June 16, 2023. The beneficial ownership of our voting Common Stock is based on 660,742,623 shares of Common
Stock outstanding as of June 16, 2023. The beneficial ownership&nbsp;percentages set forth below do not take into account shares
of Common Stock reserved for issuance under the Amended and Restated Nutex Health&nbsp;Inc. 2022 Equity Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except as described above and unless otherwise
indicated, we believe that all persons named in the table below have sole voting and investment power with respect to all shares of Common
Stock beneficially owned by them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Name of Beneficial Owner</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Amount&nbsp;and&nbsp;Nature&nbsp;of&nbsp;Beneficial<BR> Ownership</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Percent&nbsp;of&nbsp;Class</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Dr. Thomas T. Vo <SUP>(1)</SUP></FONT></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">268,322,776</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">40.42</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Premier Macy Management Holdings, LLC<SUP>(2)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">41,964,832</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.35</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Dr. Danniel Stites, Director <SUP>(3)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,355,375</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Warren Hosseinion, President and Director <SUP>(4)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,930,047</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Mitchell Creem, Director <SUP>(5)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">393,866</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Cheryl Y. Grenas, Director<SUP>(6)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Michael L. Reed, Director <SUP>(7)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">John J. Waters, Director <SUP>(8)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">558,320</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Jon C. Bates, CFO <SUP>(9)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">188,515</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Elisa Luqman, Chief Legal Officer (&ldquo;SEC&rdquo;) and Secretary <SUP>(10)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">679,976</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Pamela W. Montgomery, Chief Legal Officer (Healthcare) <SUP>(11)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">61,505</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Executive Officers and Directors as a Group</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">319,475,212</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">48.35</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">*</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Less than 1%</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.5in; font-size: 10pt; text-align: left">(1)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Micro Hospital Holding LLC (&ldquo;MHH&rdquo;) is the direct beneficial owner of 267,322,776 shares of Common Stock.&nbsp;&nbsp;Dr. Vo, the Chairman and Chief Executive Officer of the Company, as the 100% owner and sole manager of MHH, is &lrm;the indirect beneficial owner of such shares. Vo Family Limited Partnership ("VFLP") is the direct beneficial owner of 1,000,000 shares of Commn Stock. Dr. Vo, the Chairman and Chief Executive Officer of the Company, as the 100% sole trustee of VFLP, is &lrm;the indirect beneficial owner of such shares.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">(2)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Premier Macy Management Holdings, LLC is the direct beneficial owner of 41,964,832 shares of Common Stock. Each of Dr.&nbsp;Young and Cynthia J. Young, as co-trustees of the First Amended&nbsp;&amp; Restated Matthew Stephen Young&nbsp;&amp; Cynthia Jane Young Joint Living Trust, the 99% owner of Macy GP LLC, the 100% owner of Premier Macy Management Holdings, LLC, can be deemed to be the indirect beneficial owners of the shares reported herein.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left; width: 0.5in">(3)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Stites PLLC (&ldquo;STITES&rdquo;) is the direct beneficial owner of 5,355,375 shares of Common Stock.&nbsp;&nbsp;Dr. Stites as the 100% owner and sole manager of STITES, is an indirect beneficial owner of such shares.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">(4)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Includes options to purchase 200,000 shares of the common stock at $1.50 per share, options to purchase 600,000 shares of the common stock at $1.61 per share, options to purchase 859,779 shares of the common stock at $2.75 per share and a warrant to purchase 21,590 shares of the common stock at $6.67 per share.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">(5)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">The Creem Family Trust (&ldquo;CREEM&rdquo;), the direct beneficial owner of 81,746 shares of Common Stock.&nbsp;&nbsp;Mitchell Creem,&nbsp;&nbsp;the a co-trustee of CREEM, is &lrm;the indirect beneficial owner of such shares.&nbsp;&nbsp;Includes options to purchase 10,120 shares of the common stock at $5.56 per share, options to purchase 75,000 shares of common stock at $1.50 per share, options to purchase 45,000 shares at $1.61 and options to acquire 182,000 shares of common stock at $2.75 per share.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">(6)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Includes 10,000 shares of common stock held by Xavier Grenas,&nbsp;&nbsp;Ms. Grenas' husband.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">(7)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Michael L Reed Trust IRA (&ldquo;MLRTIRA&rdquo;), the direct beneficial owner of 10,000 shares of Common Stock.&nbsp;&nbsp;Micheal L Reed,&nbsp;&nbsp;the sole trustee of MLRTIRA, is &lrm;the indirect beneficial owner of such shares.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">(8)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Includes&nbsp;&nbsp;options to purchase, 102,800 shares of common stock at $1.50, 45,000 common shares at $1.61 per share,&nbsp;&nbsp;warrants to purchase 32,258&nbsp;&nbsp;shares of common stock at $1.55 per share and options to acquire 182,000 shares of common stock at $2.75 per share.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">(9)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Includes 148,515 Restricted Stock Units (RSUs) vesting 1/3 on April 1, 2023 the date of grant,&nbsp;&nbsp;1/3 on March 1, 2024 and 1/3 on March 1, 2025.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">(10)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Includes 1,370 shares of common stock held by Muhammad Luqman, Ms. Luqman&rsquo;s husband, options to purchase 117,106 shares of the commons stock at $1.50 per share, options to purchase 400,000 shares of the common stock at $1.61 per share and options to purchase 150,000 shares of common stock at $2.75 per share.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">(11)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Includes 49,505 Restricted Stock Units (RSUs) vesting 1/3 on April 1, 2023 the date of grant,&nbsp;&nbsp;1/3 on March 1, 2024 and 1/3 on March 1, 2025.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sp1_007"></A>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus covers the offering for resale from time to time, in one or more offerings, of up to an aggregate of 90,226,077 shares
of our Common Stock, which were issued to affiliates who are former holders of member interests of Nutex Holdco in connection with the
consummation of the Merger (as defined below) on April 1, 2022, and who elected to be included in this prospectus as selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nutex&nbsp;&ndash;
Clinigence Merger. </I></FONT>On April&nbsp;1, 2022, Nutex Health Holdco LLC and Clinigence Holdings,&nbsp;Inc. completed the merger contemplated
by the Agreement and Plan of Merger dated as of November&nbsp;23, 2021 between Clinigence, Nutex Acquisition LLC, a wholly-owned subsidiary
of Clinigence, Nutex, Micro Hospital Holding LLC (solely for the purposes of certain sections of the Merger Agreement), Nutex Health Holdco
LLC and Thomas Vo, M.D., solely in his capacity as the representative of the equity holders of Nutex. Immediately following the completion
of the Merger, Clinigence amended its certificate of incorporation and bylaws to change its name to &ldquo;Nutex Health&nbsp;Inc.&rdquo;
(the &ldquo;Merger&rdquo;). In connection with the Merger, each outstanding equity interest of Nutex Health Holdco LLC was exchanged for
3.571428575 shares of Clinigence common stock, or an aggregate of 592,791,712 shares of Common Stock. The Merger was accounted for as
a reverse business combination under U.S. GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-indent: 0.4in">A contractual lockup agreement with
respect to 197,597,237 of shares issued to former holders of member interests in Nutex Health Holdco LLC expired on October 1, 2022, and
the lockup for an additional 197,597,237 shares of Common Stock issued to former holders of member interests of Nutex Holdco expired on
April 1, 2023. The lockup for the remaining one-third will expire on October 1, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0.4in">The selling stockholders listed in the
table below may from time to time offer and sell any or all of the shares of Common Stock set forth below pursuant to this prospectus.
When we refer to the &ldquo;selling stockholders&rdquo; in this prospectus, we refer to the persons listed in the table below, and the
pledgees, donees, transferees, assignees, successors and other permitted transferees that hold any of the selling stockholders&rsquo;
interest in the shares of Common Stock after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0.4in">The following tables set forth information
concerning the shares of Common Stock that may be offered from time to time by each selling stockholder. The number of shares of Common
Stock beneficially owned by each selling stockholder is determined under rules issued by the SEC. Under these rules, beneficial ownership
includes any shares of Common Stock as to which the individual or entity has sole or shared voting power or investment power. Percentage
ownership is based on 660,742,603 shares of Common Stock outstanding as of June 16, 2023. In computing the number of shares of Common
Stock beneficially owned by an individual or entity and the percentage ownership of that person, shares of Common Stock subject to options,
warrants or other rights held by such person that are currently exercisable or will become exercisable within 60 days of June 16, 2023
are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of
any other person. Unless noted otherwise, the address of all listed selling stockholders is 6030 S. Rice Ave., Suite C., Houston, Texas
77081, c/o Corporate Secretary, Nutex Health Inc. Each of the selling stockholders listed has sole voting and investment power with respect
to the shares beneficially owned by the selling stockholder unless noted otherwise, subject to community property laws where applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth certain information
provided by or on behalf of the selling stockholders concerning the Common Stock that may be offered from time to time by each selling
stockholder pursuant to this prospectus. The selling stockholders identified below may have sold, transferred or otherwise disposed of
all or a portion of their securities after the date on which they provided us with information regarding their securities. Any changed
or new information given to us by the selling stockholders, including regarding the identity of, and the securities held by, each selling
stockholder, will be set forth in a prospectus supplement or amendments to the registration statement of which this prospectus is a part,
if and when necessary. A selling stockholder may sell all, some or none of such securities in any offering. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except as noted below, all selling stockholders
are former holders of member interests in Nutex Health Holdco LLC who received shares of Common Stock on April&nbsp;1, 2022 in exchange
for their contribution of member interests in Nutex Health Holdco&nbsp;LLC. We and our hospital facilities have financial and operating
relationships with multiple Physician LLCs and Real Estate Entities owned by such former holders of member interests in Nutex Health Holdco&nbsp;LLC.
Neither we nor our hospitals have a direct or indirect ownership interest in any of the Physician LLCs or Real Estate Entities. Except
as noted below, the former holders of member interests in Nutex Health Holdco LLC are not deemed &ldquo;affiliates&rdquo; of the Company.
There are no agreements among such holders with respect to the voting of the shares of Common Stock they own.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 39%"></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: center"><B>Shares Beneficially Owned Prior to Offering</B></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: center"><B>Number of Shares Being </B></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: center"><B>Shares Beneficially Owned After the Offering<SUP>(1)</SUP></B></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top"><B>Name of Selling Stockholder</B></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><B>Number</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><B>Percentage</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><B>Offered</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><B>Number</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><B>Percentage</B></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Micro Hospital Holding LLC(2)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;267,322,776</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">40.46.</TD>
    <TD STYLE="vertical-align: bottom">%</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">89,107,592</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;178,215,184</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">26.97</TD>
    <TD STYLE="vertical-align: bottom">%</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top">Stites, PLLC (3)</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">&nbsp;5,355,375</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">*&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">1,118,485</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">4,236,890</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">&nbsp;*</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top">Total</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">272,678,151</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">41.27</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">%</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">90,226,077</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">182,452,074</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">27.61</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"></TD>
    <TD STYLE="vertical-align: top; text-align: left">*</TD>
    <TD STYLE="font-size: 10pt; text-align: left">less than 1%</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.5in; font-size: 10pt; text-align: left">(1)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">We do not know when or in what amounts the selling stockholders may offer shares for sale. The selling stockholders might not sell any or all of the shares offered by this prospectus. Because the selling stockholders may offer all or some of the shares pursuant to this offering, and because there are currently no agreements, arrangements or understandings with respect to the sale of any of the shares, we cannot estimate the number of the shares that will be held by the selling stockholders after completion of the offering. However, for purposes of this table, we have assumed that, after completion of the offering, none of the shares covered by this prospectus will be held by the selling stockholders.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">(2)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Micro Hospital Holding LLC (&ldquo;MHH&rdquo;) is the direct beneficial owner of 267,322,776 shares of Common Stock. Dr.&nbsp;Vo, the Chairman and Chief Executive Officer of the Company, as the 100% owner and sole manager of MHH, is deemed to be the indirect beneficial owner of such shares. The principal business address for MHH and Dr.&nbsp;Vo is 6030 S. Rice Ave., Suite&nbsp;C, Houston, Texas 77081.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">(3)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Stites PLLC ("STITES") is the direct beneficial owner of 5,355,375 shares of Common Stock.&nbsp;&nbsp;Dr.&nbsp;Stites as the 100% owner and sole manager of STITES, is an indirect beneficial owner of such shares.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sp1_008"></A>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>The following description of the capital stock
of Nutex Health&nbsp;Inc. (the &ldquo;Company&rdquo; or &ldquo;we&rdquo;) is based upon the Company&rsquo;s amended and restated certificate
of incorporation, the Company&rsquo;s second amended and restated bylaws and applicable provisions of law. We have summarized certain
portions of the Company&rsquo;s amended and restated certificate of incorporation and second amended and restated bylaws below. The summary
is not complete and is subject to, and is qualified in its entirety by express reference to, the provisions of applicable law and to the
Company&rsquo;s amended and restated certificate of incorporation and second amended and restated bylaws.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorized Capital Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The authorized capital stock of the Company consists
of 900,000,000 shares of Common Stock, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Rights</I></B></FONT><I>.</I> Holders of shares of Common Stock are entitled to one vote per share held of record on all matters to be
voted upon by the shareholders. The holders of Common Stock do not have cumulative voting rights in the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividend
Rights</I></B></FONT><I>.</I> Holders of shares of our Common Stock are entitled to ratably receive dividends when and if declared by
our board of directors out of funds legally available for that purpose, subject to any statutory or contractual restrictions on the payment
of dividends and to any prior rights and preferences that may be applicable to any outstanding preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidation
Rights</I></B></FONT><I>.</I> Upon our liquidation, dissolution, distribution of assets or other winding up, the holders of Common Stock
are entitled to receive ratably the assets available for distribution to the shareholders after payment of liabilities and the liquidation
preference of any of our outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Matters</I></B></FONT><I>.</I> The shares of Common Stock have no preemptive or conversion rights and are not subject to further calls
or assessment by us. There are no redemption or sinking fund provisions applicable to the Common Stock. All outstanding shares of our
Common Stock, are fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Effects of Provisions of Our Amended and Restated
Certificate of Incorporation, Our Second Amended and Restated Bylaws and Delaware Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some provisions of Delaware law, and our amended
and restated certificate of incorporation and our second amended and restated bylaws described below, contain provisions that could make
the following transactions more difficult: acquisitions of us by means of a tender offer, a proxy contest or otherwise, or removal of
our incumbent officers and directors. These provisions may also have the effect of preventing changes in our management. It is possible
that these provisions could make it more difficult to accomplish or could deter transactions that shareholders may otherwise consider
to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for
our shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These provisions, summarized below, are expected
to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking
to acquire control of us to first negotiate with us. We believe that the benefits of increased protection and our potential ability to
negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging
these proposals because, among other things, negotiation of these proposals could result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Delaware Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are subject to the anti-takeover provisions
of the Delaware General Corporation Law (&ldquo;DGCL&rdquo;), including Section&nbsp;203. Under these provisions, if anyone becomes an
 &ldquo;interested stockholder,&rdquo; the Company may not enter into a &ldquo;business combination&rdquo; with that person for three&nbsp;years
without special approval, which could discourage a third party from making a takeover offer and could delay or prevent a change of control.
For purposes of Section&nbsp;203 of the DGCL, &ldquo;interested stockholder&rdquo; means, generally, someone owning 15% or more of the
Company&rsquo;s outstanding voting stock or an affiliate of the Company that owned 15% or more of the Company&rsquo;s outstanding voting
stock during the past three&nbsp;years, subject to certain exceptions as described in Section&nbsp;203 of the DGCL. As such, Section&nbsp;203
of the DGCL could prohibit or delay mergers or a change in control and may discourage attempts by other companies to acquire the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amended and Restated Certificate of Incorporation and Second Amended
and Restated Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Provisions of our amended and restated certificate
of incorporation and our second amended and restated bylaws may delay or discourage transactions involving an actual or potential change
in control or change in our management, including transactions in which shareholders might otherwise receive a premium for their shares,
or transactions that our shareholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely
affect the price of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Provisions in our amended and restated certificate
of incorporation and second amended and restated bylaws establish advance notice procedures with regard to shareholder proposals relating
to the nomination of candidates for election as directors or new business to be brought before meetings of our shareholders. These procedures
provide that notice of shareholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which
the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90&nbsp;days
nor more than 120&nbsp;days prior to the first anniversary date of the annual meeting for the preceding&nbsp;year. Our second amended
and restated bylaws specify the requirements as to form and content of all shareholders&rsquo; notices. These requirements may preclude
shareholders from bringing matters before the shareholders at an annual or special meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forum Selection</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our second amended and restated bylaws provide
that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will, to the
fullest extent permitted by applicable law, be the sole and exclusive forum for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any derivative action or proceeding brought on our behalf;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our
shareholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any action asserting a claim against us or any director or officer or other employee of ours arising pursuant to any provision of
the DGCL, our amended and restated certificate of incorporation or our second amended and restated bylaws; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any action asserting a claim against us or any director or officer or other employee of ours that is governed by the internal affairs
doctrine.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our second amended and restated bylaws also provide
that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice
of, and to have consented to, this forum selection provision. The forum selection provision is not, however, intended to be deemed a waiver
by any stockholder with respect to our compliance with U.S. federal securities laws, and the application of the forum selection provision
may in some instances be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although we believe these provisions benefit us
by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions
may have the effect of discouraging lawsuits against our directors, officers, employees and agents. The enforceability of similar exclusive
forum provisions in other companies&rsquo; certificates of incorporation or bylaws has been challenged in legal proceedings, and it is
possible that, in connection with one or more actions or proceedings described above, a court could rule&nbsp;that this provision in our
second amended and restated bylaws is inapplicable or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Transfer Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The transfer agent for our Common Stock is Transfer
Online. We have agreed to indemnify Transfer Online in its role as transfer agent, its agents and each of its stockholders, directors,
officers and employees against all liabilities, including judgments, costs and reasonable counsel fees that may arise out of acts performed
or omitted for its activities in that capacity, except for any liability due to any gross negligence, willful misconduct or bad faith
of the indemnified person or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Rule&nbsp;144</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to Rule&nbsp;144, a person who has beneficially
owned restricted shares of Common Stock for at least six&nbsp;months would be entitled to sell such securities provided that (i)&nbsp;such
person is not deemed to have been one of our affiliates at the time of, or at any time during the three&nbsp;months preceding, a sale
and (ii)&nbsp;we are subject to the Exchange Act periodic reporting requirements for at least three&nbsp;months before the sale and have
filed all required reports under Section&nbsp;13 or 15(d)&nbsp;of the Exchange Act during the 12&nbsp;months (or such shorter period as
we were required to file reports) preceding the sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Persons who have beneficially owned restricted
shares of Common Stock for at least six&nbsp;months but who are our affiliates at the time of, or at any time during the three&nbsp;months
preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month
period only a number of securities that does not exceed the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>1% of the total number of shares of Common Stock then outstanding; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the average weekly reported trading volume of the Common Stock during the four calendar weeks preceding the filing of a notice on
Form&nbsp;144 with respect to the sale.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sales by our affiliates under Rule&nbsp;144 are
also limited by manner of sale provisions and notice requirements and to the availability of current public information about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sp1_009"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The shares of Common Stock beneficially owned by
the Selling Stockholders covered by this prospectus are being registered to permit the Selling Stockholders to offer and sell the offered
shares from time to time after the date of this prospectus. These sales of securities may be at fixed prices, at prevailing market prices
at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale or at negotiated
prices. We will not receive any of the proceeds from the offering by the Selling Stockholders of the offered shares. We will bear the
fees and expenses incurred by us in connection with our obligation to register the offered securities pursuant to the Registration Rights
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders may use any one or more
of the following methods when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>on the Nasdaq Capital Market or any other national securities exchange or US inter-dealer system of a registered national securities
association on which our Common Stock may be listed or quoted at the time of sale;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block
as principal to facilitate the transaction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>an exchange distribution in accordance with the rules&nbsp;of the applicable exchange;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>privately negotiated transactions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>broker-dealers may agree with the selling shareholders to sell a specified number of such securities at a stipulated price per share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>through the writing or settlement of options or other hedging transactions, whether such options exchange or otherwise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>a combination of any such methods of sale; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any other method permitted pursuant to applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A Selling Stockholder may, from time to time, pledge
or grant a security interest in some of the shares of Common Stock owned by it and, if the Selling Stockholders defaults in the performance
of its secured obligations, the pledges or secured parties may offer and sell the shares, from time to time, under this prospectus, or
under an amendment or supplement to this prospectus amending the list of the Selling Stockholders to include the pledgee, transferee,
or other successors in interest as the Selling Stockholders under this prospectus. In connection with the sale of our Common Stock or
interests therein, a Selling Stockholder may enter into hedging transactions with broker-dealers or other financial institutions, which
may in turn engage in short sales of our Common Stock in the course of hedging the positions they assume. A Selling Stockholder may also
sell our Common Stock short and deliver these securities to close out their short positions, or loan or pledge our Common Stock to broker-dealers
that in turn may sell these securities. A Selling Stockholder may also enter into option or other transactions with broker-dealers or
other financial institutions or one or more derivative securities that require the delivery to such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). A Selling Stockholder may transfer the
shares of Common Stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling
beneficial owners for purposes of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders also may resell a portion
of the offered shares in open market transactions in reliance upon Rule&nbsp;144 under the Securities Act, provided they meet the criteria
and conform to the requirements of that rule, or pursuant to other available exemptions from the registration requirements of the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders and any underwriters,
broker-dealers or agents that participate in the sale of our Common Stock or interests therein may be &ldquo;underwriters&rdquo; within
the meaning of Section&nbsp;2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale
of the Common Stock may be underwriting discounts and commissions under the Securities Act. If the Selling Stockholders are &ldquo;underwriters&rdquo;
within the meaning of Section&nbsp;2(a)(11) of the Securities Act, then the Selling Stockholders will be subject to the prospectus delivery
requirements of the Securities Act. Underwriters and their controlling persons, dealers and agents may be entitled, under agreements entered
into with us and the Selling Stockholders, to indemnification against and contribution toward specific civil liabilities, including liabilities
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent required, the Common Stock to be
sold, the respective purchase prices and public offering prices, the names of any agents, dealers or underwriters, and any applicable
discounts, commissions, concessions or other compensation with respect to a particular offer will be set forth in an accompanying prospectus
supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To facilitate the offering of the Common Stock
offered by the Selling Stockholders, certain persons participating in the offering may engage in transactions that stabilize, maintain
or otherwise affect the price of our Common Stock. This may include over-allotments or short sales, which involve the sale by persons
participating in the offering of more shares than were sold to them. In these circumstances, these persons would cover such over-allotments
or short positions by making purchases in the open market or by exercising their over-allotment option, if any. In addition, these persons
may stabilize or maintain the price of our Common Stock by bidding for or purchasing shares in the open market or by imposing penalty
bids, where by selling concessions allowed to dealers participating in the offering may be reclaimed if the shares sold by them are repurchased
in connection with the stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of
our Common Stock at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sp1_010"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The validity of the shares of Common Stock offered
by this prospectus has been passed upon by Locke Lord LLP, Houston, Texas. If applicable, additional legal matters may be passed on for
any underwriters, dealers or agents by counsel we will name in the applicable prospectus supplement, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sp1_011"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The consolidated financial statements of Nutex Health Inc. as of December&nbsp;31,
2022 and 2021 and for each of the three the years in the period ended December&nbsp;31, 2022, and the effectiveness of the Company&rsquo;s
internal control over financial reporting incorporated by reference from the <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479681/000155837023002713/nutx-20221231x10k.htm"><FONT STYLE="color: blue">Annual
Report on Form&nbsp;10-K of Nutex Health,&nbsp;Inc. for the year ended December&nbsp;31, 2022</FONT></A> have been audited by Marcum LLP,
independent registered public accounting firm, as stated in their reports. Such financial statements are incorporated by reference in
reliance upon the reports of such firm, given their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sp1_012"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&rsquo;s
website at <U>http://www.sec.gov</U>. Copies of certain information filed by us with the SEC are also available on our website at <U>http://www.nutexhealth.com</U>.
Our website is not a part of this prospectus and is not incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus is part of a registration statement
we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules&nbsp;and
regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated
subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration
statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings.
You should review the complete document to evaluate these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sp1_013"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The SEC allows us to incorporate by reference much
of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly
available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus.
Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings
may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the
SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated
by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No.&nbsp;001-41346)
and any future filings we make with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act (in each case, other
than those documents or the portions of those documents not deemed to be filed) until the offering of the securities under the registration
statement is terminated or completed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479681/000155837023002713/nutx-20221231x10k.htm"><FONT STYLE="color: blue">Annual report on Form&nbsp;10-K for the&nbsp;year ended December&nbsp;31, 2022;</FONT></A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479681/000110465923042612/tm2311866d1_10ka.htm"><FONT STYLE="color: blue">Form&nbsp;10-K/A</FONT></A> as filed with the Commission on April&nbsp;6, 2023;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">Quarterly report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479681/000155837023009892/nutx-20230331x10q.htm"><FONT STYLE="color: blue">Form&nbsp;10-Q</FONT></A> for the quarter ended March&nbsp;31, 2023;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">Current reports on Form&nbsp;8-K filed on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479681/000160706223000002/nutx010423form8k.htm"><FONT STYLE="color: blue">January&nbsp;4, 2023</FONT></A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479681/000155837023002711/nutx-20230302x8k.htm"><FONT STYLE="color: blue">March&nbsp;2, 2023</FONT></A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479681/000110465923042250/tm2311866d2_8k.htm"><FONT STYLE="color: blue">April&nbsp;5, 2023</FONT></A> (with the exception of Item&nbsp;2.02 and Exhibit&nbsp;99.1, which are furnished, not filed), <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479681/000110465923044380/tm2310592d8_8k.htm"><FONT STYLE="color: blue">April&nbsp;12, 2023</FONT></A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479681/000155837023007550/nutx-20230501x8k.htm"><FONT STYLE="color: blue">May&nbsp;2, 2023</FONT></A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479681/000155837023009897/nutx-20230515x8k.htm"><FONT STYLE="color: blue">May&nbsp;15, 2023</FONT></A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479681/000155837023010549/nutx-20230522x8k.htm"><FONT STYLE="color: blue">May&nbsp;26, 2023</FONT></A>; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">The description of the Common Stock contained in <A HREF="https://www.sec.gov/Archives/edgar/data/1479681/000160706222000548/ex4_6.htm"><FONT STYLE="color: blue">Exhibit&nbsp;4.6</FONT></A> to Nutex&rsquo;s Annual report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479681/000155837023002713/nutx-20221231x10k.htm"><FONT STYLE="color: blue">Form&nbsp;&lrm;&lrm;10-K</FONT></A> for the year ended December&nbsp;31, 2022 filed on March&nbsp;3, 2023. &lrm;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A statement contained in a document incorporated
by reference into this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement
contained in this prospectus, any prospectus supplement or in any other subsequently filed document which is also incorporated in this
prospectus modifies or replaces such statement. Any statements so modified or superseded shall not be deemed, except as so modified or
superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may request a copy of these documents, which
will be provided to you at no cost, by writing or telephoning us using the following contact information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nutex Health&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Corporate Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">6030 S. Rice Ave, Suite&nbsp;C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Houston, Texas 77081</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone: (713) 660-0557</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2310592d6_424b3img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2310592d6_424b3img001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1"  ^ =D# 2(  A$! Q$!_\0
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MAG]I']GW1O#OBC4+&SUCQM=0:M:VMT\<=Y&($(210<. 2>OK4?\ PU'^W?\
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MI?\ I+'7T[0 5R?QF^$=A\:? T_@6^\:^)?#R3S1RG5/">L-8WJ;&W +*H)
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MX4<5]%5\H_\ !*;5?$&L^&/C!K'BKPPVBZG>?'#6I=0T=[@3FPG:.W+P&10
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**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
